“SMAC”-Down for the Apoptosis-Restoring Drug, Xevinapant: What Does Its Story Reveal?
- 30 July 2026
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (19) , 4234-4245
Abstract
Xevinapant, an antagonist of inhibitor of apoptosis proteins (IAP) from the second mitochondrial activator of caspases (SMAC)–mimetic drug class, was developed to restore apoptosis in cancer cells. Preclinical studies demonstrated on-target IAP degradation, caspase activation, and proinflammatory apoptosis via TNFα upregulation. Monotherapy activity was modest in both preclinical and phase I studies, pointing to a primarily synergistic role as a (chemo)radiosensitizer, with the strongest antitumor signals observed in head and neck squamous cell carcinoma (HNSCC). In the Debio1143-201 phase II trial in locally advanced HNSCC, adding xevinapant to chemoradiation dramatically improved locoregional control and suggested favorable long-term survival, raising hopes for the first practice-changing advance in concomitant chemoradiotherapy in two decades. Unexpectedly, the TrilynX phase III trial was definitively negative, showing detrimental effects on survival and greater toxicity, which halted the development of SMAC mimetics as anticancer drugs. High intratumoral drug exposure was confirmed, but supporting pharmacodynamic data were largely derived from indirect proapoptotic signals in peripheral blood biomarkers. In this study, we review xevinapant’s trajectory, highlighting both the promise and risks of apoptosis-directed therapies, and extract key lessons for future oncology drug development by examining existing preclinical evidence, pharmacodynamic biomarkers, trial design and interpretation, and challenges associated with dosing agents that have a narrow therapeutic index.Keywords
Funding Information
- Institute of Cancer Research
This publication has 66 references indexed in Scilit:
- Evasion of apoptosis and treatment resistance in squamous cell carcinoma of the head and neckCancer Treatment Reviews, 2024
- Model‐Informed Selection of the Recommended Phase III Dose of the Inhibitor of Apoptosis Protein Inhibitor, Xevinapant, in Combination with Cisplatin and Concurrent Radiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and NeckClinical Pharmacology & Therapeutics, 2023
- Letter to the Editor: SMAC mimetics inhibit human T cell proliferation and fail to augment type 1 cytokine responsesCellular Immunology, 2023
- SMAC mimetics inhibit human T cell proliferation and fail to augment type 1 cytokine responsesCellular Immunology, 2023
- Censored patients in Kaplan–Meier plots of cancer drugs: An empirical analysis of data sharingEuropean Journal of Cancer, 2020
- Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs)Apoptosis, 2017
- Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man studyCancer Chemotherapy and Pharmacology, 2015
- Initial testing (stage 1) of LCL161, a SMAC mimetic, by the pediatric preclinical testing programPediatric Blood & Cancer, 2011
- Immunohistochemical detection of X-linked inhibitor of apoptosis in head and neck squamous cell carcinomaAnnals of Diagnostic Pathology, 2007
- Nuclear expression of cIAP-1, an apoptosis inhibiting protein, predicts lymph node metastasis and poor patient prognosis in head and neck squamous cell carcinomasCancer Letters, 2005